Cargando…
Central anandamide deficiency predicts stress-induced anxiety: behavioral reversal through endocannabinoid augmentation
Stress is a major risk factor for the development of mood and anxiety disorders; elucidation of novel approaches to mitigate the deleterious effects of stress could have broad clinical applications. Pharmacological augmentation of central endogenous cannabinoid (eCB) signaling may be an effective th...
Autores principales: | Bluett, R J, Gamble-George, J C, Hermanson, D J, Hartley, N D, Marnett, L J, Patel, S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4119220/ https://www.ncbi.nlm.nih.gov/pubmed/25004388 http://dx.doi.org/10.1038/tp.2014.53 |
Ejemplares similares
-
Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation
por: Hermanson, Daniel J., et al.
Publicado: (2013) -
Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors
por: Bedse, Gaurav, et al.
Publicado: (2018) -
The endocannabinoid anandamide is an airway relaxant in health and disease
por: Simon, Annika, et al.
Publicado: (2022) -
Metabolism of the Endocannabinoid Anandamide: Open Questions after 25 Years
por: Maccarrone, Mauro
Publicado: (2017) -
The Role of the Endocannabinoids 2-AG and Anandamide in Clinical
Symptoms and Treatment Outcome in Veterans with PTSD
por: Leen, N.A., et al.
Publicado: (2022)